Healing the Patient of Tomorrow
Products on well-understood commercialization tracks often take an incremental approach rather than trying to create paradigm-shifting technologies. In this blog, I’ll take a look at medical devices that are on a commercialization track to heal the patient of tomorrow in a way that is substantially better than previous offerings. They are generally broken into three broad categories based on their advantages over existing medical devices: either healing the patient at home, fixing issues with existing devices, or creating non-invasive diagnostic tools. Connected Home Use Devices Connected home-use devices allow a patient to undergo most of their recovery or treatment at home. This increases opportunities for rest and connects unedited patient data directly to the physician rather than getting a version of the story from the patient. In most cases, patients receive more physician attention than they would from visiting clinics periodically. The medical practitioner has information access on an instant feedback loop even when the patient is at home. Home-use therapy that connects directly to healthcare providers is a fantastic example of modern therapeutics and has been explored a number of times in digital health resources. Don't miss New England's largest event for medtech professionals! Get 20% off registration for the BIOMEDevice Boston Conference with promo code "MDDI". Patients using these devices can take part in their own care, where appropriate. Usage a...
The objective of this compound is to decrease the rate of rectal toxicity related to radiation therapy, by creating a gap between the prostate and rectum. Secondary benefits include decreased urinary complications and improved sexual quality of life. The hydrogel spacer maintains space for approximately 3 months, and is absorbed in about 6 months.
To evaluate the efficacy and clinical impact of 3 Tesla in-bore trans-rectal magnetic resonance-guided biopsy (3T MRGB) for prostate cancer (PCa) detection based on PIRADSv2 in patients with either suspected prostate cancer or under active surveillance.
We describe our experience using MRI fused CBCT guidance for prostate biopsy. There are no published reports on the use of CBCT guidance in prostate biopsies. We hypothesize this technique will have an adequate safety profile while accurately detecting prostate cancer.
Image-guided thermal ablation has become the standard of care for treating early stage liver cancer. However, a significant limitation to a successful ablation procedure is the heat-sink effect, which may lead to suboptimal thermal dose delivery. Currently, there is no reliable method for quantifying the heat-sink effect due to limited information on blood vessel flow and its associated anatomy relative to the ablation zone. The purpose of this study was to use 4D-flow MRI to map out liver flow patterns and correlate flow rates with ablation zone volumes.
Catheter malfunction and occlusion remains a common detriment of dialysis catheters. Analysis of RA anatomy on 3D imaging reviewed that the anterior posterior diameter of the RA is longer than the lateral. Preclinical studies with a dialysis catheter designed to be compatible with this feature of RA anatomy are presented herein.
We report the immediate flow response and incidence of steal syndrome following detapering of dialysis grafts.
To investigate whether the time interval from thrombosis to percutaneous intervention for clotted dialysis access arterovenous fistulas (AVFs) and arterovenous grafts (AVGs) has a significant effect on clinical outcomes and patency.
To evaluate safety and effectiveness of yttrium-90 radioembolization to treat hepatic metastases in uveal melanoma patients that also received adjuvant immunotherapy.
Biphenotypic hepatocellular-cholangiocarcinoma (HCC-CC) is a rare type of primary liver cancer that carries a poor prognosis. Since most patients present at a stage too advanced for surgical resection, loco-regional liver directed therapy is often performed for palliative or downstaging purposes. The purpose of this study is to evaluate patient outcomes after Yttrium-90 radioembolization (Y90) in patients with HCC-CC.
Immunotherapy is a paradigm-shifting advance in cancer care, but the overall response rates remain low. There has been a renaissance in the concept of promoting the immune-responsiveness of the tumor immune microenvironment via intratumoral (IT) delivery of immunostimulatory agents. However, the optimal method for IT delivery of such medications that maximizes IT dispersion while minimizing perilesional leakage and systemic distribution is unknown. The purpose of this study was to characterize IT drug distribution and its influence on drug efficacy using conventional end-hole needles (EHNs) versus multi-sidehole needles (MSHN).